Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012

[1]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[2]  A. Gennery,et al.  Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants , 2015, Bone Marrow Transplantation.

[3]  P. Sonneveld,et al.  The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. , 2015, Leukemia research.

[4]  G. Ossenkoppele,et al.  How I treat the older patient with acute myeloid leukemia. , 2015, Blood.

[5]  R. Gale,et al.  Should persons with acute myeloid leukemia have a transplant in first remission? , 2014, Leukemia.

[6]  Bernd Holleczek,et al.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. , 2014, The Lancet. Oncology.

[7]  M. Nørgaard,et al.  Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study , 2014, Leukemia.

[8]  B. Johansson,et al.  Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience , 2014, Blood Cancer Journal.

[9]  A. Hagemeijer,et al.  High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Schlenk,et al.  Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. , 2013, Hematology. American Society of Hematology. Education Program.

[11]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Jemal,et al.  Outcome of older patients with acute myeloid leukemia , 2013, Cancer.

[13]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[15]  C. Stiller,et al.  Incidence, survival and prevalence of myeloid malignancies in Europe. , 2012, European journal of cancer.

[16]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[17]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Scher,et al.  Under-representation of older adults in cancer registration trials: known problem, little progress. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Juliusson,et al.  Acute myeloid leukemia in the real world: why population-based registries are needed. , 2012, Blood.

[20]  S. Devesa,et al.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.

[21]  L. Möllgård,et al.  Hematopoietic stem cell transplantation rates and long‐term survival in acute myeloid and lymphoblastic leukemia , 2011, Cancer.

[22]  M. Schymura,et al.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. , 2011, Blood.

[23]  M. Höglund,et al.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry , 2011, Leukemia.

[24]  Augustin Ferrant,et al.  Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.

[25]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[27]  Franz Király,et al.  Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Pasquini,et al.  Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[31]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[32]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[33]  P. Dickman,et al.  Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. , 2009, Blood.

[34]  J. Cavenagh,et al.  Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre , 2009, British journal of haematology.

[35]  E. Estey,et al.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.

[36]  H. Brenner,et al.  Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century , 2008, Haematologica.

[37]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[38]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[39]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[40]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[41]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[42]  P. Dickman,et al.  Interpreting trends in cancer patient survival , 2006, Journal of internal medicine.

[43]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[44]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[45]  M. Fey,et al.  Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[47]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[48]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[49]  J. Fernández-Rañada,et al.  About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain. , 1996, Blood.

[50]  J A Knottnerus,et al.  Completeness of cancer registration in Limburg, The Netherlands. , 1993, International journal of epidemiology.

[51]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[52]  T. Hakulinen,et al.  Cancer survival corrected for heterogeneity in patient withdrawal. , 1982, Biometrics.

[53]  S. Chevret,et al.  Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  W. Hiddemann,et al.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[56]  C. Earle,et al.  Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly , 2005, Drugs & aging.

[57]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[58]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[59]  S. Preston‐Martin,et al.  High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. , 1996, Blood.